Market Overview:
The global acute agitation and aggression treatment market is expected to grow at a CAGR of 7.5% from 2018 to 2030. The growth in the market can be attributed to the increasing incidence of psychiatric disorders, growing geriatric population, and rising demand for better healthcare facilities. Based on type, the oral segment is expected to account for the largest share of the global market in 2018. This segment is projected to grow at a CAGR of 7.8% from 2018 to 2030 due to its easy availability and low cost as compared with other types of treatments. Based on application, hospitals & ambulatory surgical centers are expected to account for the largest share of the global market in 2018.
Product Definition:
Acute Agitation and Aggression Treatment is the term used for the treatment of agitation and aggression that are present in a short-term, time-limited manner. The importance of Acute Agitation and Aggression Treatment is that it can help to prevent more serious behaviors from developing, as well as helping to ensure the safety of both the individual who is experiencing agitation or aggression and those around them.
Oral:
Oral is a drug that modifies the behavior of an individual by changing the brain chemistry. It’s an off-label drug used for treatment of acute agitation and aggressive behavior in patients suffering from mental disorders such as bipolar disorder, schizophrenia, etc. The U.S FDA has not approved it as a cure but rather as an anti-epileptic drug which can reduce some types of seizures in certain patients with epilepsy.
Intramuscular Injection:
Intramuscular injection is a medication technique in which the drug is injected into muscle tissues. The most commonly used drugs for intramuscular injections are benzodiazepines, anesthetic agents, opioids, and local anesthetics. Intravenous injections can be done by two routes; namely intravenous injection and subcutaneous injection.
Application Insights:
Based on application, the global acute agitation and aggression treatment market is segmented into hospitals & ambulatory surgical centers, psychiatric care facilities and others. The hospital & ambulatory surgical center segment dominated the market in 2017 owing to factors such as a large patient base with chronic diseases or injuries requiring medical attention, emergency room (ER) visits due to physical fights among patients being treated for acute conditions. In addition, this segment has been gaining traction due to an increase in number of healthcare providers per capita across developed countries including U.S., Germany and France which is expected to drive growth over the forecast period.
Regional Analysis:
North America dominated the global market in 2017. The presence of key players, availability of advanced treatment options, and high adoption rate for acute agitation and aggression treatments are some factors responsible for its large share. Moreover, increasing prevalence of chronic diseases such as cardiovascular disorders and respiratory problems due to a rise in geriatric population is also expected to drive the demand for AATs in North America during the forecast period.
Asia Pacific is anticipated to witness lucrative growth over the forecast period owing to rising healthcare expenditure by governments along with an increase in awareness about available treatment options among patients & their families. In addition, growing medical tourism industry due to low cost of procedures performed at home compared with those performed at international hospitals will further boost this regional market during the forecast years.
Growth Factors:
- Increasing prevalence of acute agitation and aggression
- Growing demand for effective and rapid treatment options
- Rising awareness about available treatment options
- Technological advancements in the field of acute agitation and aggression treatment
- Growing number of clinical studies on acute agitation and aggression
Scope Of The Report
Report Attributes
Report Details
Report Title
Acute Agitation and Aggression Treatment Market Research Report
By Type
Oral, Intramuscular Injection, Others
By Application
Hospitals & Ambulatory Surgical Centers, Psychiatric Care Facilities, Others
By Companies
Eli Lilly and Company, Pfizer, Ono Pharmaceutical, Otsuka Holdings, GlaxoSmithKline, Bristol-Myers Squibb, Johnson & Johnson, H. Lundbeck A/S
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
205
Number of Tables & Figures
144
Customization Available
Yes, the report can be customized as per your need.
Global Acute Agitation and Aggression Treatment Market Report Segments:
The global Acute Agitation and Aggression Treatment market is segmented on the basis of:
Types
Oral, Intramuscular Injection, Others
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Hospitals & Ambulatory Surgical Centers, Psychiatric Care Facilities, Others
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Eli Lilly and Company
- Pfizer
- Ono Pharmaceutical
- Otsuka Holdings
- GlaxoSmithKline
- Bristol-Myers Squibb
- Johnson & Johnson
- H. Lundbeck A/S
Highlights of The Acute Agitation and Aggression Treatment Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Oral
- Intramuscular Injection
- Others
- By Application:
- Hospitals & Ambulatory Surgical Centers
- Psychiatric Care Facilities
- Others
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Acute Agitation and Aggression Treatment Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Acute agitation and aggression treatment is a type of mental health care that helps people who are experiencing an intense, uncontrolled outburst of anger or violence. Treatment typically includes medication and therapy.
Some of the major players in the acute agitation and aggression treatment market are Eli Lilly and Company, Pfizer, Ono Pharmaceutical, Otsuka Holdings, GlaxoSmithKline, Bristol-Myers Squibb, Johnson & Johnson, H. Lundbeck A/S.
The acute agitation and aggression treatment market is expected to grow at a compound annual growth rate of 7.5%.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Acute Agitation and Aggression Treatment Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Acute Agitation and Aggression Treatment Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Acute Agitation and Aggression Treatment Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Acute Agitation and Aggression Treatment Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Acute Agitation and Aggression Treatment Market Size & Forecast, 2018-2028
4.5.1 Acute Agitation and Aggression Treatment Market Size and Y-o-Y Growth
4.5.2 Acute Agitation and Aggression Treatment Market Absolute $ Opportunity
Chapter 5 Global Acute Agitation and Aggression Treatment Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Acute Agitation and Aggression Treatment Market Size Forecast by Type
5.2.1 Oral
5.2.2 Intramuscular Injection
5.2.3 Others
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Acute Agitation and Aggression Treatment Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Acute Agitation and Aggression Treatment Market Size Forecast by Applications
6.2.1 Hospitals & Ambulatory Surgical Centers
6.2.2 Psychiatric Care Facilities
6.2.3 Others
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Acute Agitation and Aggression Treatment Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Acute Agitation and Aggression Treatment Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Acute Agitation and Aggression Treatment Analysis and Forecast
9.1 Introduction
9.2 North America Acute Agitation and Aggression Treatment Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Acute Agitation and Aggression Treatment Market Size Forecast by Type
9.6.1 Oral
9.6.2 Intramuscular Injection
9.6.3 Others
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Acute Agitation and Aggression Treatment Market Size Forecast by Applications
9.10.1 Hospitals & Ambulatory Surgical Centers
9.10.2 Psychiatric Care Facilities
9.10.3 Others
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Acute Agitation and Aggression Treatment Analysis and Forecast
10.1 Introduction
10.2 Europe Acute Agitation and Aggression Treatment Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Acute Agitation and Aggression Treatment Market Size Forecast by Type
10.6.1 Oral
10.6.2 Intramuscular Injection
10.6.3 Others
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Acute Agitation and Aggression Treatment Market Size Forecast by Applications
10.10.1 Hospitals & Ambulatory Surgical Centers
10.10.2 Psychiatric Care Facilities
10.10.3 Others
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Acute Agitation and Aggression Treatment Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Acute Agitation and Aggression Treatment Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Acute Agitation and Aggression Treatment Market Size Forecast by Type
11.6.1 Oral
11.6.2 Intramuscular Injection
11.6.3 Others
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Acute Agitation and Aggression Treatment Market Size Forecast by Applications
11.10.1 Hospitals & Ambulatory Surgical Centers
11.10.2 Psychiatric Care Facilities
11.10.3 Others
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Acute Agitation and Aggression Treatment Analysis and Forecast
12.1 Introduction
12.2 Latin America Acute Agitation and Aggression Treatment Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Acute Agitation and Aggression Treatment Market Size Forecast by Type
12.6.1 Oral
12.6.2 Intramuscular Injection
12.6.3 Others
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Acute Agitation and Aggression Treatment Market Size Forecast by Applications
12.10.1 Hospitals & Ambulatory Surgical Centers
12.10.2 Psychiatric Care Facilities
12.10.3 Others
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Acute Agitation and Aggression Treatment Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Acute Agitation and Aggression Treatment Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Acute Agitation and Aggression Treatment Market Size Forecast by Type
13.6.1 Oral
13.6.2 Intramuscular Injection
13.6.3 Others
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Acute Agitation and Aggression Treatment Market Size Forecast by Applications
13.10.1 Hospitals & Ambulatory Surgical Centers
13.10.2 Psychiatric Care Facilities
13.10.3 Others
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Acute Agitation and Aggression Treatment Market: Competitive Dashboard
14.2 Global Acute Agitation and Aggression Treatment Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Eli Lilly and Company
14.3.2 Pfizer
14.3.3 Ono Pharmaceutical
14.3.4 Otsuka Holdings
14.3.5 GlaxoSmithKline
14.3.6 Bristol-Myers Squibb
14.3.7 Johnson & Johnson
14.3.8 H. Lundbeck A/S
